Springworks Drug Patent Portfolio
Springworks owns 2 orange book drugs protected by 41 US patents Given below is the list of Springworks's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12029711 | Dosage forms of mirdametinib | 15 Mar, 2044 | Active |
| US11872211 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US11925619 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US11925620 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US11938116 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US11951096 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US11957662 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US12011434 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US12011435 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US12036207 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US12138246 | Treatments with nirogacestat | 19 May, 2043 | Active |
| US11806322 | Mirdametinib treatment | 16 Mar, 2043 | Active |
| US11839595 | Mirdametinib treatment | 16 Mar, 2043 | Active |
| US11883375 | Mirdametinib treatment | 16 Mar, 2043 | Active |
| US12220390 | Mirdametinib treatment | 16 Mar, 2043 | Active |
| US11807611 | Chlorinated tetralin compounds and pharmaceutical compositions | 08 Sep, 2042 | Active |
| US11844780 | Chlorinated tetralin compounds and pharmaceutical compositions | 08 Sep, 2042 | Active |
| US11504354 | Chlorinated tetralin compounds and pharmaceutical compositions | 08 Jul, 2042 | Active |
| US11612588 | Chlorinated tetralin compounds and pharmaceutical compositions | 08 Jul, 2042 | Active |
| US12110277 | Synthesis of nirogacestat | 08 Jul, 2042 | Active |
| US11066358 | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | 17 Feb, 2041 | Active |
| US11084780 | Door construction | 17 Feb, 2041 | Active |
| US11453641 | Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | 17 Feb, 2041 | Active |
| US11571402 | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | 17 Feb, 2041 | Active |
| US11806321 | Non-linear dosing of mirdametinib | 17 Feb, 2041 | Active |
| US11819487 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib | 17 Feb, 2041 | Active |
| US12011424 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib | 17 Feb, 2041 | Active |
| US12037306 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | 17 Feb, 2041 | Active |
| US12090128 | Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof | 17 Feb, 2041 | Active |
| US10590087 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof | 09 Aug, 2039 | Active |
| US10710966 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof | 09 Aug, 2039 | Active |
| US10941118 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof | 09 Aug, 2039 | Active |
| US11820748 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof | 09 Aug, 2039 | Active |
| US11845732 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof | 09 Aug, 2039 | Active |
| US11884634 | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide | 09 Aug, 2039 | Active |
| US11884635 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof | 09 Aug, 2039 | Active |
| US11905255 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof | 09 Aug, 2039 | Active |
| US12116347 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof | 09 Aug, 2039 | Active |
| US7342118 | Imidazole compounds for the treatment of neurodegenerative disorders | 18 Aug, 2025 | Active |
| US7795447 | Imidazole compounds for the treatment of neurodegenerative disorders | 18 Aug, 2025 | Active |
| US7951958 | Imidazole compounds for the treatment of neurodegenerative disorders | 11 Mar, 2025 | Expired |
Latest Legal Activities on Springworks's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Springworks.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Electronic Review
Critical
| 07 Jun, 2024 | US11951096 |
| Second letter to regulating agency to determine regulatory review period | 26 Apr, 2024 | US7951958 |
| Second letter to regulating agency to determine regulatory review period | 26 Apr, 2024 | US7795447 |
| Second letter to regulating agency to determine regulatory review period | 26 Apr, 2024 | US7342118 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US7951958 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US7342118 |
|
Email Notification
Critical
| 17 Apr, 2024 | US11957662 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US7795447 |
| Mail Patent eGrant Notification | 16 Apr, 2024 | US11957662 |
| Recordation of Patent eGrant | 16 Apr, 2024 | US11957662 |
|
Recordation of Patent Grant Mailed
Critical
| 16 Apr, 2024 | US11957662 |
| Patent eGrant Notification | 16 Apr, 2024 | US11957662 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 Apr, 2024 | US11957662 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951096 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Apr, 2024 | US11951096 |
Springworks's Family Patents
Springworks Drug List
Given below is the complete list of Springworks's drugs and the patents protecting them.
1. Gomekli
Gomekli is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12029711 | Dosage forms of mirdametinib |
15 Mar, 2044
(18 years from now)
| Active |
| US11806322 | Mirdametinib treatment |
16 Mar, 2043
(17 years from now)
| Active |
| US11839595 | Mirdametinib treatment |
16 Mar, 2043
(17 years from now)
| Active |
| US11883375 | Mirdametinib treatment |
16 Mar, 2043
(17 years from now)
| Active |
| US12220390 | Mirdametinib treatment |
16 Mar, 2043
(17 years from now)
| Active |
| US11066358 | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
17 Feb, 2041
(15 years from now)
| Active |
| US11084780 | Door construction |
17 Feb, 2041
(15 years from now)
| Active |
| US11453641 | Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
17 Feb, 2041
(15 years from now)
| Active |
| US11571402 | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
17 Feb, 2041
(15 years from now)
| Active |
| US11806321 | Non-linear dosing of mirdametinib |
17 Feb, 2041
(15 years from now)
| Active |
| US11819487 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
17 Feb, 2041
(15 years from now)
| Active |
| US12011424 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
17 Feb, 2041
(15 years from now)
| Active |
| US12037306 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
17 Feb, 2041
(15 years from now)
| Active |
| US12090128 | Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof |
17 Feb, 2041
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gomekli's drug page
2. Ogsiveo
Ogsiveo is protected by 27 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11872211 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US11925619 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US11925620 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US11938116 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US11951096 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US11957662 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US12011434 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US12011435 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US12036207 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US12138246 | Treatments with nirogacestat |
19 May, 2043
(18 years from now)
| Active |
| US11807611 | Chlorinated tetralin compounds and pharmaceutical compositions |
08 Sep, 2042
(17 years from now)
| Active |
| US11844780 | Chlorinated tetralin compounds and pharmaceutical compositions |
08 Sep, 2042
(17 years from now)
| Active |
| US11504354 | Chlorinated tetralin compounds and pharmaceutical compositions |
08 Jul, 2042
(17 years from now)
| Active |
| US11612588 | Chlorinated tetralin compounds and pharmaceutical compositions |
08 Jul, 2042
(17 years from now)
| Active |
| US12110277 | Synthesis of nirogacestat |
08 Jul, 2042
(17 years from now)
| Active |
| US10590087 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
09 Aug, 2039
(14 years from now)
| Active |
| US10710966 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
09 Aug, 2039
(14 years from now)
| Active |
| US10941118 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
09 Aug, 2039
(14 years from now)
| Active |
| US11820748 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
09 Aug, 2039
(14 years from now)
| Active |
| US11845732 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
09 Aug, 2039
(14 years from now)
| Active |
| US11884634 | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
09 Aug, 2039
(14 years from now)
| Active |
| US11884635 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
09 Aug, 2039
(14 years from now)
| Active |
| US11905255 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
09 Aug, 2039
(14 years from now)
| Active |
| US12116347 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
09 Aug, 2039
(14 years from now)
| Active |
| US7342118 | Imidazole compounds for the treatment of neurodegenerative disorders |
18 Aug, 2025
(4 months from now)
| Active |
| US7795447 | Imidazole compounds for the treatment of neurodegenerative disorders |
18 Aug, 2025
(4 months from now)
| Active |
| US7951958 | Imidazole compounds for the treatment of neurodegenerative disorders |
11 Mar, 2025
(20 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ogsiveo's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List